Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Expands Opioid Abuse Research, Outreach

Executive Summary

US agency signs contracts for more real-world data on abuse; officials also meet with AMA representatives to discuss opioid prescriber education.

You may also be interested in...

US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts

Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.

FDA Contract Awards In Brief: Regenerative Medicine, eCTD, Reg Science

Contracts US agency awarded as fiscal year 2017 came to a close include one to Nexight for a regenerative medicine standards development process, another to Lorenz to manage eCTD submissions – and 26 more for regulatory science R&D.

Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort

Reeducating prescribers on treating pain will take a long time, FDA Commissioner Scott Gottlieb tells Senate HELP Committee Members.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts